Dynagen Zotrim
Executive Summary
Mova will market a combination treatment for urinary tract infection under an agreement announced Aug. 11. Zotrim combines two commonly prescribed drugs in "compliance packaging." Dynagen will manufacture the product for Mova through its subsidiary, Able Labs. Mova will provide funds for completion of the Zotrim NDA, to be filed in the fourth quarter of 1998. Dynagen estimates the agreement's value at $1 mil. in the first year and $1.5 mil. per year thereafter